-
Clinical Chemistry 07/2012; 58(9):1273-4. · 7.91 Impact Factor
-
Clinical Chemistry 10/2010; 56(12):1783-5. · 7.91 Impact Factor
-
Clinical Chemistry 08/2008; 54(7):1101-3. · 7.91 Impact Factor
-
Clinical Chemistry 08/2008; 54(7):1241-4. · 7.91 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This prospective study assessed the clinical application of a nonfasting low-density lipoprotein cholesterol measure in a pediatric primary care population. A homogenous direct low-density lipoprotein cholesterol assay was tested in healthy children, aged 4 to 12 years, at risk for hyperlipidemia, as defined by American Academy of Pediatrics, and including patients with incomplete family histories. This nonfasting homogeneous assay was comparable to modified beta quantification, the gold standard reference method of measuring low-density lipoprotein cholesterol, and the current recommended screening method, total cholesterol. Results from the study suggest that this nonfasting assay can provide more direct low-density lipoprotein cholesterol measurements for healthy children, with improved clinical utility and greater overall patient convenience in testing for important cholesterol abnormalities.
Clinical Pediatrics 07/2007; 46(5):441-5. · 1.15 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Homocysteine is an essential amino acid, whose clinical utilization includes detection of homocystinuria, vitamin B12 and folate deficiencies and cardiovascular disease management. We report assay performance of the Catch reagents on the Hitachi 917 chemistry analyzer.
Linearity, recovery, imprecision and interference from lipids, bilirubin, hemoglobin and ascorbic acid were determined on a Hitachi 917 chemistry analyzer. Split sample aliquots were assayed using the described method, by HPLC and fluorescence polarization immunoassay for method comparisons.
The assay was linear to at least 45 micromol/l. Intra- and interassay variation ranged from 1.7% to 3.4% and 3.3% to 6.7%, respectively. Interference was observed when hemoglobin concentrations was >7 g/l and intralipid >5 g/l. No interference was observed from bilirubin or ascorbic acid. The assay was in good agreement with values obtained by HPLC and fluorescence polarization immunoassay.
The performance of the Catch homocysteine assay was acceptable on the Hitachi 917 chemistry analyzer.
Clinica Chimica Acta 05/2005; 354(1-2):117-22. · 2.54 Impact Factor
-
Clinical Chemistry 12/2004; 50(11):2157-9. · 7.91 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Coronary heart disease (CHD) is the major cause of death in the developed world and screening for conventional cardiovascular risk factors fails to identify more than 50% of the individuals who will present with acute coronary syndromes. Chronic inflammation appears to play a significant role in the initiation and development of atherosclerosis. Recent investigations have shown an association between inflammatory markers such as C-reactive protein (CRP) and CHD. These markers have proven useful as prognostic indicators in acute coronary syndromes and in predicting future coronary events in apparently healthy men and women. The availability of high sensitivity CRP (hs-CRP) assays has been crucial in exploring the role of this acute phase reactant in primary prevention settings. In this review, we discuss the evidence associating these inflammatory markers, especially CRP, with the pathogenesis of atherosclerosis and acute coronary syndromes, and we address the mechanism of risk as well as the clinical utility of this marker.
Critical Reviews in Clinical Laboratory Sciences 10/2002; 39(4-5):459-97. · 5.25 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Coronary vascular disease (CVD) has a high prevalence in the United States, yet 40-50% of those with that diagnosis have normal or mildly increased cholesterol levels. Increased C-reactive protein (CRP) has been associated with CVD, in those presenting after an acute coronary event, and also in apparently healthy individuals.
We reviewed the literature on this association, and on the relationship between CRP and traditional CVD risk factors including smoking, hypertension, cholesterol and obesity. Also examined is the effect of various medications used in patients with CVD on CRP concentrations.
CRP correlates with risk of CVD in patients who have a history of acute coronary disease, stable angina, and in those who have never been diagnosed with CVD. CRP imparts risk that is independent of hyperlipidemia.
Once commercially available CRP assays are shown to be reliable, CRP may help predict short- and long-term cardiovascular outcomes and may have a role in CVD screening analogous to that of lipid. In the future CRP may modify treatment and preventive therapies.
Clinica Chimica Acta 04/2002; 317(1-2):1-15. · 2.54 Impact Factor
